We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Boston Scientific Corporation
Health Care · Health Care Equipment
Structural: medical-device compounder levered to two procedural growth engines - Watchman LAA closure (AFib stroke prevention) and FARAPULSE pulsed field ablation (AFib first-line). PFA is the fastest device launch in EP history; FARAPULSE captured majority US share within 12 months of approval and is cannibalising RF/cryo from $JNJ and $MDT.
Watchman compounds mid-teens on AFib prevalence + guideline tailwind. Endoscopy + urology (Rezum, SpaceOAR) provide non-cardio diversification.
PFA TAM expanding from paroxysmal to persistent AFib (FDA expansion pending); Watchman penetration <15% of eligible AFib population; pipeline (Watchman FLX Pro, AVANT GUARD trial) extends franchise; gross margin mix-up as PFA scales; M&A optionality (Axonics-style tuck-ins).
$JNJ Varipulse + $MDT PulseSelect closing the PFA gap with bigger sales forces; Watchman growth decelerates as easy AFib pool depletes; capital-intensive consumable mix; hospital capex pressure if rate cycle re-tightens; valuation premium (~30x fwd EPS) leaves no margin for execution slip.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.